Acarix Reports Remarkable 2024 Financial Results
Sales and revenue for the CADScor System are thriving, particularly bolstered by robust U.S. expansion efforts. Acarix, a front-runner in advanced AI and acoustics-based cardiac diagnostics, unveiled its financial performance for the year.
Significant Growth and Strategic Partnerships
Acarix has exhibited exceptional advancement in operational excellence, underlined by a collaborative statement from the leadership team about substantial growth in their product lines and expanding market footprints. Their focus on innovation within the cardiac diagnostics space continues to bear fruit, enhancing their sales through strategic partnerships and increased accessibility.
A Strong Year in Cardiovascular Market
The CEO, Aamir Mahmood, praised the transformational year, highlighting that the fourth quarter was particularly strong with impressive figures that include a staggering 333% increase in CADScor System placements. Additionally, patch sales revenues soared by 88%, representing significant trust from the medical community and prompting a new partnership with Geo-Med, LLC to extend their reach to U.S. Veterans.
Financial Highlights from 2024
Throughout the fourth quarter, Acarix notched a notable revenue surge—total revenues reached SEK 1,700 thousand, reflecting a substantial 45% increase year-over-year. Key metrics include:
- U.S. patch revenue up by 88%, totaling SEK 873 thousand.
- Operating costs showed a 27% decline, reflecting efficiency improvements.
- Despite a reported loss of SEK -16,020 thousand, adjusted figures indicate strong resilience with a significant 32% improvement from the previous year.
Yearly Performance Overview
Analyzing the full year, Acarix reported total revenue of SEK 6,202 thousand. The comprehensive review also noted a 27% growth in patches sold, signifying heightened demand in the U.S. market and beyond. The systems deliveries reached a rising total of 62 units, marking a remarkable 51% increase.
Anticipated Future Developments
As Acarix eyes 2025, plans are in place for continuous growth through geographic expansion and a focus on clinical studies. Mahmood expressed gratitude towards the team and shareholders, reinforcing the idea that the trajectory for the upcoming years looks promising. The company is strategically equipped with a solid balance sheet and a well-defined strategic plan.
Positive Implications of CMS Decisions
The favorable CMS ruling allowing fixed reimbursement for the CADScor System will lay the groundwork for significant U.S. growth in the forthcoming year. Acarix aims to leverage these opportunities while ensuring that their innovations continue to meet the needs of healthcare professionals and patients alike.
About Acarix
Acarix is at the forefront of medical devices aimed at rapid diagnoses of coronary artery disease (CAD) at the point of care. Their flagship CADScor System, which is CE approved and FDA DeNovo cleared, addresses the needs for effective, non-invasive diagnostic procedures, having been implemented with over 29,000 patients.
Frequently Asked Questions
What were Acarix's main financial achievements for 2024?
Acarix's financial achievements included a 45% increase in total revenue, with a significant rise in system placements and patch sales.
How did Acarix's operating costs change in 2024?
Operating costs decreased by 27% compared to the previous year due to enhanced operational efficiencies.
What strategic partnerships has Acarix formed recently?
Acarix has formed a partnership with Geo-Med, LLC to expand the CADScor System's reach to U.S. Veterans.
What is the outlook for Acarix moving forward?
The company is positioned for continued growth, with plans for geographic expansion and a focus on clinical studies in 2025.
What is the purpose of the CADScor System?
The CADScor System is designed to detect significant coronary artery disease non-invasively and accurately at the point of care.
